Monopar Therapeutics Inc. (NasdaqCM: MNPR)
Health Care · Biotechnology · US
$110.82
+2.88% today · +254.1% 1Y
Monopar Therapeutics Inc. (NasdaqCM: MNPR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $723.04M and employs 22 people.
Over the last twelve months the share price has gained 254.1%, trading between 29.18 and 124.82.
Tweenvest scores Monopar Therapeutics Inc. across four factors: quality 36/100. Its strongest factor is quality.
MNPR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $723.04M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.18
- Dividend yield
- —
- Beta (5Y)
- 1.51
- 52-week high
- $124.82
- 52-week low
- $29.18
- Avg volume (3M)
- —
- Shares outstanding
- 6.71M
- Employees
- 22
- Next earnings
- —
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
- ISIN
- US61023L2079
- Founded
- 2014
- Listed since
- Dec 19, 2019
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.